<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Neuropsychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Neuropsychopharmacol</journal-id><journal-id journal-id-type="publisher-id">ijnp</journal-id><journal-title-group><journal-title>International Journal of Neuropsychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">1461-1457</issn><issn pub-type="epub">1469-5111</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5616244</article-id><article-id pub-id-type="doi">10.1093/ijnp/pyw041.308</article-id><article-id pub-id-type="publisher-id">pyw041.308</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Monday Abstracts</subject></subj-group></subj-group></article-categories><title-group><article-title>PM308. A phase 3, multicenter randomized double blind placebo controlled study of the opioid receptor antagonist &#x02013;Odelepran the treatment of alcohol addiction.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Krupitsky</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mukhametshina</surname><given-names>E.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Samsonov</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Department of Addictions, St.-Petersburg Bekhterev Research Psychoneurological Institute, Russia</aff><aff id="aff2">
<label>2</label>R - Pharm CJSC, Russia</aff><pub-date pub-type="collection"><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub" iso-8601-date="2016-05-27"><day>27</day><month>5</month><year>2016</year></pub-date><volume>19</volume><issue>Suppl 1</issue><fpage seq="a">10</fpage><lpage>10</lpage><permissions><copyright-statement>&#x000a9; The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</copyright-statement><copyright-year>2016</copyright-year></permissions><self-uri xlink:href="pyw041.308.pdf"/><counts><page-count count="1"/></counts></article-meta></front><body><p>
<bold>Abstract</bold>
</p><p>Educational Objectives: Odelepran is a new pan opioid receptor antagonist for the treatment of alcohol dependence. Odelepran demonstrates high in vitro binding affinity (K<italic>i</italic>) and antagonist potency (K<italic>b</italic>) at all 3 classic human opioid receptors (mu, kappa, and delta).</p><p>Odelepran has a potential to decrease the amount of alcohol drunk by a patient, as well as to block the effects of opiates, thus helping patients to abstain from using these potent substances of abuse. The preclinical research programme for peroral Odelepran formulation is completed by now, as are phase I and phase II clinical studies in patients with alcohol dependence.</p><p>Methods: This was multi-center randomized double blind placebo controlled phase III clinical studies for assessment of efficacy and safety of Odelepran with a 24-week treatment period. Patients (N = 644) were alcohol-dependent, treatment-seeking adults. Clinical trial was in Russia.</p><p>Inclusion criteria: patients with alcohol dependence of moderate severity (5&#x02013;12 drinks/day). Primary endpoint: the mean number of drinks per drinking day. Medical Management on compliance issue only to reduce placebo effect.</p><p>Analysis for genotyping: the coding target preparation OPRM1 rs1799971.</p><p>To assess the efficacy we used psychometric scales: Retrospective analysis of alcohol consumption (TLFB), Assessment of the consequences of drinking (questionnaire DrInC-2R), Assessment of craving for alcohol (Obsessive-Compulsive Scale), Subjective assessment of the patient quality of life (SF-36).</p><p>Conclusions: in clinical trial was included 644 patients with alcohol-dependent (DSM-V/ISD-10): Female- 192 patients, Men- 452 patients and a average age from 25&#x02013;49.</p><p>Interim safety analysis showed no serious adverse effects, good tolerability and fewer drink per day compared with placebo. The final data will be presented in June 2016.</p></body></article>